UBS maintains Pfizer at Neutral, PT $39.00

UBS maintains Pfizer at Neutral, PT $39.00

An UBS analyst maintained Pfizer (NYSE: PFE) at Neutral and a price target of $39.00 from a prior price target of $41.00.

Prior to this rating, Pfizer had 12 buy ratings, 13 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Pfizer, click here. For more news on Pfizer, click here.

Pfizer's stock price closed at $38.49. They are down -7.25% in the last month and down -21.51% in the last 12 months.

According to Investing Pro, Pfizer's fair value is $55.08, an upside of 43.10%. Pfizer's fair value comes with a low degree of uncertainty, according to InvestingPro.

Check out Pfizer's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or